
SI-BONE reported 1Q25 orthopedic sales of $47.3 million, up 24.9% compared to the first quarter of 2024.
The company maintained its momentum with strong first quarter revenue performance and a record 1,400 active physicians. The physician base grew 27% year-over-year and more than doubled since the first quarter of 2022.
“We’re experiencing broad-based demand for our existing technologies and rapid adoption of our new solutions launched last year,” said SI-BONE CEO Laura Francis. “With an active pipeline of novel technologies under development, we believe our procedure volume growth will be amplified as we launch these new solutions over the next 12 to 18 months. Our innovative platform is driving deeper engagement and market penetration as we add physicians at a record pace.”
The company expects 2025 full-year revenue between $193.5 million to $197.5 million, representing growth between 16% and 18%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $47.3 | $37.9 | $9.4 | 24.9% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $44.8 | $35.4 | $9.4 | 26.6% |
| OUS | $2.5 | $2.4 | $0.0 | 0.5% |
| Total | $47.3 | $37.9 | $9.4 | 24.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $47.3 | |
| Cost of Sales | $9.6 | 20.3% |
| Sales and Marketing | $30.7 | 64.9% |
| General and Admin | $10.0 | 21.1% |
| General and Admin | $10.0 | 21.1% |
| R & D | $4.5 | 9.6% |
| Other | ($0.9) | (2%) |
SI-BONE reported 1Q25 orthopedic sales of $47.3 million, up 24.9% compared to the first quarter of 2024.
The company maintained its momentum with strong first quarter revenue performance and a record 1,400 active physicians. The physician base grew 27% year-over-year and more than doubled since the first quarter of 2022.
"We're...
SI-BONE reported 1Q25 orthopedic sales of $47.3 million, up 24.9% compared to the first quarter of 2024.
The company maintained its momentum with strong first quarter revenue performance and a record 1,400 active physicians. The physician base grew 27% year-over-year and more than doubled since the first quarter of 2022.
“We’re experiencing broad-based demand for our existing technologies and rapid adoption of our new solutions launched last year,” said SI-BONE CEO Laura Francis. “With an active pipeline of novel technologies under development, we believe our procedure volume growth will be amplified as we launch these new solutions over the next 12 to 18 months. Our innovative platform is driving deeper engagement and market penetration as we add physicians at a record pace.”
The company expects 2025 full-year revenue between $193.5 million to $197.5 million, representing growth between 16% and 18%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $47.3 | $37.9 | $9.4 | 24.9% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $44.8 | $35.4 | $9.4 | 26.6% |
| OUS | $2.5 | $2.4 | $0.0 | 0.5% |
| Total | $47.3 | $37.9 | $9.4 | 24.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $47.3 | |
| Cost of Sales | $9.6 | 20.3% |
| Sales and Marketing | $30.7 | 64.9% |
| General and Admin | $10.0 | 21.1% |
| General and Admin | $10.0 | 21.1% |
| R & D | $4.5 | 9.6% |
| Other | ($0.9) | (2%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.





